- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Uniqure NV (QURE)
Uniqure NV stock price live, this page displays NASDAQ QURE stock exchange data. View the QURE premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Uniqure NV real time stock price chart below.
What Is the Uniqure NV Stock Price Today?
The Uniqure NV stock price today is 23.030.
What Is the Stock Symbol for Uniqure NV?
The stock symbol for Uniqure NV is "QURE."
What Stock Exchange Does Uniqure NV Trade On?
Uniqure NV is listed and trades on the NASDAQ stock exchange.
Is Uniqure NV a Good Stock to Buy?
Determining whether Uniqure NV—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the QURE quote. (ISIN: NL0010696654)
What Is the Uniqure NV Stock Price Today?
The Uniqure NV stock price today is 23.030.
What Is the Stock Symbol for Uniqure NV?
The stock symbol for Uniqure NV is "QURE."
What Stock Exchange Does Uniqure NV Trade On?
Uniqure NV is listed and trades on the NASDAQ stock exchange.
Is Uniqure NV a Good Stock to Buy?
Determining whether Uniqure NV—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the QURE quote. (ISIN: NL0010696654)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
21.510
24.215
52 wk Range
8.730
51.720
QURE is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
21.51024.215
52 wk Range
8.73051.720
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
QURE Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
60.670
Upside
+163.44%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
4 analysts have revised their earnings downwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell
Analyst Ratings
11 Buy
2 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 60.670
(+163.44% Upside)
Uniqure NV Earnings Call Summary for Q3/2026
- uniQure posted Q3 2026 adjusted loss of $0.88/share, beating estimates of $0.92, though revenue of $5.19M missed forecasts by 16.43%.
- FDA accepted AMT-130 BLA for Huntington's disease with Priority Review; PDUFA decision date set for May 1, 2027; U.K. application validated.
- Cash position of $768.4M expected to fund operations into 2030; SG&A expenses rose 23.2% YoY as firm builds commercial infrastructure.
- Confirmatory study to enroll ~200 patients globally with 36-month endpoint; U.S. screening begins by end-2026; targeting 15+ launch centers.
- Updated data for AMT-260 (epilepsy) and AMT-191 (Fabry disease) expected H1 2027; shares rose 1.38% premarket on regulatory progress.
Last Updated: 11/04/2026, 10:28 PM
Read Full TranscriptEarnings
Latest Release
Nov 04, 2026
EPS / Forecast
-0.88 / -0.92
Revenue / Forecast
5.19M / 6.21M
Compare QURE to Peers and Sector
Metrics to compare | QURE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipQUREPeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.3x | 4.9x | −0.2x | |
PEG Ratio | 1.32 | 0.04 | 0.00 | |
Price/Book | 4.9x | 2.8x | 2.6x | |
Price / LTM Sales | 85.6x | 3.5x | 2.8x | |
Upside (Analyst Target) | 162.7% | 228.7% | 62.7% | |
Fair Value Upside | Unlock | 17.5% | 8.0% | Unlock |
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Uniqure NV (QURE) Stock Price Today?
The Uniqure NV stock price today is 23.030 USD.
What Stock Exchange Does Uniqure NV Trade On?
Uniqure NV is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Uniqure NV?
The stock symbol for Uniqure NV is "QURE."
What Is the Uniqure NV Market Cap?
As of today, Uniqure NV market cap is 1.600B USD.
What Is Uniqure NV's Earnings Per Share (TTM)?
The Uniqure NV EPS (TTM) is -4.04.
When Is the Next Uniqure NV Earnings Date?
Uniqure NV will release its next earnings report on Mar 01, 2027.
From a Technical Analysis Perspective, Is QURE a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Uniqure NV Stock Split?
Uniqure NV has split 0 times.
How Many Employees Does Uniqure NV Have?
Uniqure NV has 221 employees.
What is the current trading status of Uniqure NV (QURE)?
As of Nov 05, 2026, Uniqure NV (QURE) is trading at a price of 23.030 USD, with a previous close of 23.030 USD. The stock has fluctuated within a day range of 21.510 USD to 24.215 USD, while its 52-week range spans from 8.730 USD to 51.720 USD.
What Is Uniqure NV (QURE) Price Target According to Analysts?
The average 12-month price target for Uniqure NV is 60.670 USD, with a high estimate of 91.98310811 USD and a low estimate of 28.1295045 USD. 11 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +163.44% Upside potential.
What Is the QURE After Hours Price?
QURE's last after hours stock price is 23.020 USD, the stock has decreased by -0.050, or -0.220%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.